[Special Stock] Clinomics Achieves World's First Complete Human Genome Sequencing... Expected to Set Global Benchmark in Precision Disease Prediction

[Asia Economy Reporter Hyungsoo Park] Clinomics is on the rise. The news that it has succeeded in securing candidate genetic biomarkers associated with early myocardial infarction by utilizing a large amount of genome big data appears to have influenced its stock price.

As of 1:59 PM on the 8th, Clinomics is trading at 8,610 KRW, up 23.5% from the previous trading day.

Clinomics explained that through genome association analysis of hundreds of healthy individuals and heart patients, a path has opened to distribute a product worldwide that can predict sudden acute heart failure in advance.

This was achieved through close cooperation with the Ulsan Genome Center at UNIST, Ulsan University Hospital, Ulsan Hospital, and others, supported by the Korean 10,000-person genome project led by Ulsan City. By precisely analyzing the genomes of healthy individuals and patients, they confirmed that genetic mutations related to thrombosis, fibrinolysis, inflammation, and lipid metabolism are associated with early myocardial infarction.

The most significant feature of the study is that it utilized whole genome sequencing, which decodes the entire human genome with high accuracy, rather than the conventional selective genome decoding (DNA-chip) that analyzes only some genome regions for the first time in the world.

Jonghwa Park, CEO of Clinomics, said, "We have secured technology to predict and diagnose myocardial infarction and will develop and distribute a world-class product for heart disease diagnosis," adding, "We are conducting further validation and commercialization of the research results."

Through the production of vast big data, they discovered 85 new genetic mutation markers related to early myocardial infarction that were previously unknown. It is expected that in the future, anyone will be able to predict and prevent myocardial infarction early with a simple genetic test.

Samples from 596 early myocardial infarction patients, who are difficult to obtain, and 643 healthy control group participants who voluntarily joined the Ulsan 10,000-person genome project were directly collected at Ulsan Hospital and Ulsan University Hospital. Whole genome sequencing was conducted over several years on samples collected through the biobanks of Chungbuk National University Hospital, Gyeongsang National University Hospital, and Kyung Hee University Hospital. The research team compared and analyzed genetic mutations between patients and healthy individuals using information analysis with a supercomputer for ultra-high-performance genome big data analysis based on the whole genome sequencing results.

A company official stated, "We are currently conducting verification and optimization studies of the discovered markers using the world's highest-performance bio-data farm supercomputer infrastructure built through the Ulsan Genome Regulatory Free Zone project," adding, "Our goal is to release the world's best product that predicts the risk of future myocardial infarction disease as quickly as possible."

This content was produced with the assistance of AI translation services.